Dr Christian Holm Hansen

Honorary Associate Professor

United Kingdom

I have a background in mathematics and medical statistics and joined LSHTM in early 2014 after previously working at the University of Edinburgh, including at the Edinburgh Clinical Trials Unit. From 2014 to 2020 I was based in East Africa, first in Tanzania at Mwanza Intervention Trials Unit (MITU), and subsequently at the MRC/UVRI/LSHTM Uganda Unit where I headed the Statistics section. I currently also hold a position with Statens Serum Institut in Copenhagen primarily working on infectious disease epidemiology.

Affiliations

Department of Infectious Disease Epidemiology and International Health

Faculty of Epidemiology and Population Health

Teaching

At LSHTM I currently teach on the Practical Research Skills module (module number 3462 - slot C1) for which I have been a module organiser since 2016. I currenly also supervise two PhD students registered at LSHTM.

Beyond LSHTM I also teach on the ECDC funded Europe

Research

HIV prevention research; infectious disease epidemiology; statistical modelling; clinical trials; research methodology; estimation of vaccine effectiveness.

Selected Publications

Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.

ANYWAINE, Z; Wright, D; Warimwe, GM; Kaleebu, P; Elliott, A; HANSEN, C;

2025

BMJ public health

Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study.

HANSEN, CH; Lassaunière, R; Rasmussen, M; Moustsen-Helms, IR; Valentiner-Branth, P;

2025

The Lancet infectious diseases

Impact of the dual rapid diagnostic test for HIV and syphilis among pregnant women: a before and after health center-based study in Central Uganda (2018-2019).

BAHEMUKA, U; Hall, L; Okimat, P; ABAASA, A; HANSEN, CH; MAYAUD, P;

2025

International Journal of Infectious Diseases

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.

KANSIIME, S; HOLM HANSEN, C; Bern, H; Fox, J; Dunn, D; RUZAGIRA, E; HAYES, R; Mc Cormack, S;

2025

HIV Research & Clinical Practice

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial

Borges, ÁH; Russell, M; Tait, D; Scriba, TJ; Nemes, E; Skallerup, P; Van Brakel, E; Cabibbe, AM; Cirillo, DM; Leuvennink-Steyn, M; Rutkowski, KT; Wood, GK; Thierry-Carstensen, B; Tingskov, PN; Meldgaard, EC; Kristiansen, MP; Søndergaard, RE; HANSEN, CH; Follmann, F; Jensen, CG; Gela, A; Ntinginya, NE; Ruhwald, M; Shenje, J; White, L; ... POR TB study group,

2025

The Lancet. Infectious diseases

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomised, Factorial, Non-Inferiority Trial

Dunn, DT; McCormack, S; Kusemererwa, S; Munseri, P; Singh, N; Mutonyi, G; Bern, H; Goldwirt, L; Kingsley, C; Kroidl, A; HANSEN, CH; Ding, S; Kawuma, R; Amondi, M; Bahemuka, U; Buma, D; Clutterbuck, D; Gaffoor, Z; Jennings, A; Kakande, A; William, W; Kalanzi, B; Kisinda, A; Matsoso, M; Miller, T; ... Nzuza, A.

2025

Elsevier BV

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

KANSIIME, S; HANSEN, CH; RUZAGIRA, E; McCormack, S; HAYES, R; Dunn, D;

2024

Clinical trials (London, England)

Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.

Moustsen-Helms, IR; Bager, P; Larsen, TG; Møller, FT; Vestergaard, LS; Rasmussen, M; HANSEN, CH; SSI-DMC Study Group,;

2024

The Lancet Infectious diseases

Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation.

HANSEN, CH;